The increase in price target from $3 to $5 by UBS, while maintaining a Neutral rating, suggests a positive adjustment in the valuation of Kodiak Sciences. This adjustment reflects an improved outlook or performance expectations for the company, which could lead to increased investor interest and potentially a rise in stock price in the short term.